Henlius (2696.HK) is an international innovative biopharmaceutical company with products covering oncology, autoimmune diseases, ophthalmology and other therapeutic areas. The company has built a fully integrated global platform spanning R&D, manufacturing and commercialization, with nearly 4,000 employees worldwide. As of early 2026, 10 products have been approved in more than 60 countries and regions, including 4 approved by the U.S. FDA and 5 by the European Commission. Its core product, serplulimab (trade name: Hetronifly^® in Europe), is the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of small-cell lung cancer and for perioperative gastric cancer. It has been approved in 50 markets worldwide with an accelerated globalization process. On the innovation front, the company has built a diversified, platform-based innovation technology matrix covering immune checkpoint inhibitors, immune cell engagers (including multispecific TCEs), antibody-drug conjugates (ADCs) and AI-driven early-stage R&D platforms, with more than 50 early-stage innovation assets and over 30 ongoing clinical studies globally. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius is steadily entering its "Globalization 2.0" phase, continuing to provide high-quality, affordable biologics to patients worldwide.